Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Pulmonx Corporation (NASDAQ:LUNG) has received a consensus recommendation of "Hold" from ten research firms, with one sell rating, four hold ratings, and five buy ratings.
• Recent analyst reports have significantly reduced target prices for Pulmonx, with Stifel Nicolaus dropping their price objective from $16.00 to $5.00 and Piper Sandler lowering theirs to $2.50.
• The company reported a negative EPS of ($0.38) for the last quarter, surpassing estimates but indicating ongoing financial challenges, with a revenue of $23.86 million.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) has been assigned an average recommendation of "Hold" from the ten research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $7.6643.

LUNG has been the subject of a number of research analyst reports. Stifel Nicolaus dropped their price objective on Pulmonx from $16.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, July 31st. Lake Street Capital dropped their price objective on Pulmonx from $12.00 to $8.00 and set a "buy" rating for the company in a report on Thursday, July 31st. Piper Sandler downgraded Pulmonx from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $9.00 to $2.50 in a report on Thursday, July 31st. Wall Street Zen downgraded shares of Pulmonx from a "hold" rating to a "sell" rating in a research note on Friday, October 3rd. Finally, Wells Fargo & Company cut their target price on shares of Pulmonx from $6.00 to $3.00 and set an "equal weight" rating on the stock in a research note on Friday, August 1st.

Hedge Funds Weigh In On Pulmonx

Hedge funds have recently made changes to their positions in the business. Corton Capital Inc. purchased a new position in shares of Pulmonx in the 2nd quarter valued at $32,000. R Squared Ltd purchased a new position in shares of Pulmonx in the 2nd quarter valued at $41,000. Bank of Montreal Can purchased a new position in shares of Pulmonx in the 2nd quarter valued at $53,000. Vontobel Holding Ltd. purchased a new position in shares of Pulmonx in the 1st quarter valued at $82,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Pulmonx in the 2nd quarter valued at $84,000. Hedge funds and other institutional investors own 91.04% of the company's stock.

Pulmonx Trading Up 0.6%

LUNG stock opened at $1.59 on Tuesday. The company has a market cap of $64.79 million, a price-to-earnings ratio of -1.11 and a beta of 0.42. The company has a quick ratio of 4.63, a current ratio of 5.35 and a debt-to-equity ratio of 0.54. The business has a fifty day simple moving average of $1.67 and a 200-day simple moving average of $2.98. Pulmonx has a 52 week low of $1.47 and a 52 week high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.02. The business had revenue of $23.86 million during the quarter, compared to the consensus estimate of $23.46 million. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%. Pulmonx has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Pulmonx will post -1.55 EPS for the current year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.